Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y)
- PMID: 1751373
- DOI: 10.1111/j.1365-2141.1991.tb08055.x
Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y)
Abstract
Prospective biochemical, virological and selected immunological follow up has been done for up to 32 months on 15 previously untreated haemophilic boys following treatment with an intermediate purity dry heated factor VIII concentrate (BPL 8Y). Tests for liver function and antibodies to blood-borne viruses have been assessed monthly for the first year after starting treatment and thereafter every 2 months. All patients were immunized against hepatitis B and have not developed hepatitis B core antibodies and no boy has shown any rise in alanine transaminase level nor has anyone developed antibodies to hepatitis C (HCV). All patients have remained anti-HIV seronegative. T lymphocyte subsets have been measured approximately every 4 months and in no patient has there been a significant rise in CD8+ cells; one patient showed a significant decrease in CD4+ cells but these and all CD4+ values for the other boys remained within normal age related limits. Changes in CD4+ levels in this one boy were not related to the total amount of treatment received. This group of patients who appear not to have contracted HIV, hepatitis B or non A non B hepatitis following treatment with this intermediate purity factor VIII concentrate have also not shown any consistent changes in CD4+ or CD8+ cells, which have been recorded previously in frequently treated haemophiliacs.
Comment in
-
Infusion of clotting factor concentrates in haemophilia.Br J Haematol. 1992 Aug;81(4):625. doi: 10.1111/j.1365-2141.1992.tb03011.x. Br J Haematol. 1992. PMID: 1390258 No abstract available.
Similar articles
-
Safety trial of heated factor VIII concentrate (8Y).Arch Dis Child. 1989 Oct;64(10):1463-7. doi: 10.1136/adc.64.10.1463. Arch Dis Child. 1989. PMID: 2510607 Free PMC article.
-
Long-term follow up of patients treated with intermediate FVIII concentrate BPL 8Y.Haemophilia. 1998 Mar;4(2):89-93. doi: 10.1046/j.1365-2516.1998.00153.x. Haemophilia. 1998. PMID: 9873844 Clinical Trial.
-
Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood-borne virus infection.Br J Haematol. 1995 Sep;91(1):191-6. doi: 10.1111/j.1365-2141.1995.tb05268.x. Br J Haematol. 1995. PMID: 7577631
-
The effects of type of factor VIII concentrate used in haemophilia on T-helper cell number and inhibitor incidence.Blood Coagul Fibrinolysis. 1992 Oct;3(5):597-604. doi: 10.1097/00001721-199210000-00011. Blood Coagul Fibrinolysis. 1992. PMID: 1450325 Review.
-
Clotting factor concentrates and immune function in haemophilic patients.Haemophilia. 1998 Sep;4(5):704-13. doi: 10.1046/j.1365-2516.1998.00172.x. Haemophilia. 1998. PMID: 9873875 Review.
Cited by
-
High potency factor VIII concentrates.BMJ. 1992 Feb 1;304(6822):319. doi: 10.1136/bmj.304.6822.319-b. BMJ. 1992. PMID: 1739845 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials